Menu

Theranos CEO Banned from Running Labs for Two Years

Federal regulators also revoked a certificate for the company’s Newark, California lab.

Jul 8, 2016
Tanya Lewis

Elizabeth HolmesWIKIMEDIA, GLENN FAWCETTA government health regulator has banned Elizabeth Holmes, founder and CEO of the embattled blood testing startup Theranos, from operating a lab for at least two years, the company announced yesterday (July 8). The Centers for Medicare & Medicaid Services (CMS) also yanked the certificate for its Newark, California lab, imposed an unspecified fine, and suspended approval of Medicare and Medicaid payments for lab services, according to the statement.

“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,” Holmes said in the statement. “While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance.”

The Newark lab’s revocation takes effect in two months’ time, but Theranos said it would not conduct any patient testing there “until further notice.” In the meantime, the facility will be shut down and rebuilt “from the ground up,” and the company will hire new leadership and personnel, Homes said in the statement. The company said it will continue to serve customers at its Arizona lab.

Theranos, which was founded by Holmes in 2003 and was previously valued at $9 billion, is now worth about $800 million, according to Ars Technica. Federal officials launched a criminal probe into the company following media reports questioning the accuracy of its claims. Walgreens recently ended its partnership with the company. 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.